New COVID booster vaccine tested as nasal spray and shot
NCT ID NCT07221162
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new booster vaccine called Boost-2867 in 140 healthy adults who have already been vaccinated against COVID-19. The vaccine is given either as a shot with or without adjuvants (ingredients that boost immune response) or as a nasal spray without adjuvants. The main goals are to check safety and measure the immune response, including antibodies in the blood and nose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Boost-2867 (a lab-made protein that mimics part of the COVID-19 virus spike, designed to boost immunity)
What this could lead to
If successful, this could provide a new booster option that may offer broader or longer-lasting protection against COVID-19 variants.
What could go wrong
This is an early Phase 1 trial with only 140 people, focused on safety and immune response. It is too soon to know if it will work better than existing boosters.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Immunization Research, Johns Hopkins Bloomberg School Public Health
Baltimore, Maryland, 21205, United States
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27703, United States
-
Kaiser Permanente Washington Health Research Institute
Seattle, Washington, 98101-1466, United States
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine
San Francisco, California, 94110, United States
-
University of Pittsburgh - Medicine - Infectious Diseases
Pittsburgh, Pennsylvania, 15213, United States
-
University of Rochester Medical Center - Vaccine Research Unit
Rochester, New York, 14642-0001, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States